Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer.
Koca E, Niravath PA, Ensor J, Patel TA, Li X, Hemati P, Wong H, Qian W, Boone T, Zhao J, Ramshesh PV, Cohen AL, Murthy A, Nair S, Darcourt JG, Belcheva A, Kaklamani VG, Chang JCN. Koca E, et al. Among authors: kaklamani vg. Breast Cancer Res Treat. 2021 Jul;188(2):433-439. doi: 10.1007/s10549-021-06214-7. Epub 2021 Apr 15. Breast Cancer Res Treat. 2021. PMID: 33860388 Clinical Trial.
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Kaklamani VG, Siziopikou K, Scholtens D, Lacouture M, Gordon J, Uthe R, Meservey C, Hansen N, Khan SA, Jeruss JS, Bethke K, Cianfrocca M, Rosen S, Von Roenn J, Wayne J, Parimi V, Jovanovic B, Gradishar W. Kaklamani VG, et al. Breast Cancer Res Treat. 2012 Apr;132(3):833-42. doi: 10.1007/s10549-011-1411-8. Epub 2011 Feb 27. Breast Cancer Res Treat. 2012. PMID: 21359953 Clinical Trial.
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W. Kaklamani VG, et al. Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26. Breast Cancer Res Treat. 2015. PMID: 26006067 Clinical Trial.
A pilot study of cabergoline for the treatment of metastatic breast cancer.
Costa R, Santa-Maria CA, Scholtens DM, Jain S, Flaum L, Gradishar WJ, Clevenger CV, Kaklamani VG. Costa R, et al. Among authors: kaklamani vg. Breast Cancer Res Treat. 2017 Oct;165(3):585-592. doi: 10.1007/s10549-017-4370-x. Epub 2017 Jul 3. Breast Cancer Res Treat. 2017. PMID: 28674764 Clinical Trial.
Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang TH, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K. Wu Y, et al. Among authors: kaklamani vg. Cancer Res. 2018 Feb 1;78(3):671-684. doi: 10.1158/0008-5472.CAN-17-1327. Epub 2017 Dec 6. Cancer Res. 2018. PMID: 29212856 Free PMC article.
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, Darcourt JG, Meisel JL, Li X, Zhao J, Kuhn JG, Rosato RR, Qian W, Belcheva A, Schwartz MR, Kaklamani VG, Chang JC. Patel TA, et al. Among authors: kaklamani vg. Breast Cancer Res. 2019 Sep 2;21(1):100. doi: 10.1186/s13058-019-1186-0. Breast Cancer Res. 2019. PMID: 31477168 Free PMC article. Clinical Trial.
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
Albain KS, Gray RJ, Makower DF, Faghih A, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Wood WC, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW, Sparano JA. Albain KS, et al. Among authors: kaklamani vg. J Natl Cancer Inst. 2021 Apr 6;113(4):390-399. doi: 10.1093/jnci/djaa148. J Natl Cancer Inst. 2021. PMID: 32986828 Free PMC article. Clinical Trial.
142 results